Antihypertensives in dermatology
Part II - Cutaneous adverse reactions to antihypertensives

P. S. S. Ranugha, Jayadev B. Betkerur
Department of Dermatology and Venereology, JSS Medical College and Hospital, JSS University, Mysore, Karnataka, India

Abstract
Antihypertensive drugs are prescribed frequently and can cause cutaneous adverse reactions. The exact incidence and frequency of these reactions are unknown. Multiple antihypertensive drug consumption has contributed to a substantial increase in the number of cutaneous adverse reactions to them. Thus, there is a need for dermatologists and physicians to be aware of the wide range of available antihypertensives and the type of reactions that can be expected. This review article focuses on the various clinical presentations that have been implicated or associated with them. The diagnosis and management have been discussed in brief.

Key words: Antihypertensives, cutaneous adverse drug reactions, lichenoid drug reaction, psoriasiform eruption

Introduction
Antihypertensives are used extensively for hypertension as well as other indications including migraine, alopecia, hemangioma, etc. Cutaneous adverse drug reactions to them are common, but the exact incidence and frequency are unknown. Turk et al. found these drugs to be the incriminating cause in 8.5% of hospitalized patients, preceded by antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs) and anticonvulsants. Upadhayai et al. found that 2% of such patients developed drug reactions. The information obtained from the Danish National Board of Health’s Committee on Adverse Drug Reactions showed that 10–60% of reactions caused by antihypertensives are dermatological. There is lack of comprehensive data on the incidence and different types of cutaneous reactions occurring with common and newer antihypertensives. Relevant articles from the PubMed database were collected and analyzed. Case control studies or meta-analyses which showed significant association of drugs with any cutaneous adverse drug reaction were highlighted. Observations have been mentioned as reports.

Some classes of antihypertensives are commonly associated with certain reactions.
1. Angiotensin converting enzyme (ACE) inhibitors: The overall incidence of adverse effects is estimated at 28%, approximately half of which are cutaneous. The common cutaneous reactions are potentially life threatening angioedema, pruritus, bullous eruptions, urticaria, photosensitivity and hair loss.
2. Calcium channel blockers: The most common reactions are gingival hyperplasia (21%) and flushing (10%). Other reactions described are facial or truncal telangiectasia, photosensitivity, new-onset psoriasis (as well as exacerbation), purpuric exanthems, pemphigoid, subacute cutaneous lupus erythematosus, gynecomastia, erythromelalgia and oral ulcers. The frequency of these reactions may be as high as 48%. The more serious reactions associated are toxic epidermal necrolysis with diltiazem. Stevens-Johnson syndrome, erythema multiforme and exfoliative dermatitis have been associated with all three drugs in this class. Reactions occur more frequently with diltiazem than others.
3. Beta blockers: The pathogenetic mechanism responsible is still obscure. It may be due to blockade of the epidermal cell and T-lymphocyte beta-receptors, rather than direct immunologic, allergic or toxic mechanisms. Beta blockers have been commonly associated with lichenoid drug eruptions, eczematous and psoriasiform eruptions.
4. Diuretics: Thiazides can cause vasculitis, phototoxic/allergic reaction, erythema multiforme and eczema.1 Furosemide can cause bullous pemphigoid as well as pseudoporphyria.

There are very few studies on the prevalence of cutaneous adverse drug reactions due to antihypertensives. An Indian study showed beta-blockers as the most common agent, followed by calcium channel blockers. The most common patterns observed were urticaria, followed by lichenoid drug eruptions.2 In a Danish study, amiloride and hydrochlorothiazide had the highest number of cutaneous reactions.3 The common and rare cutaneous adverse drug reactions reported with antihypertensives are tabulated [Table 1]. The individual cutaneous adverse drug reaction patterns are discussed below.

**Acute Generalized Exanthematous Pustulosis**

Acute generalized exanthematous pustulosis is characterized by the rapid development of non-follicular, sterile pustules on an erythematous base. It is attributed to drugs in most cases. Systemic involvement with hepatic, renal or pulmonary insufficiency occurs in approximately 20% of the cases.9 The eruption occurs 2 to 5 days after drug intake. Although antibiotics are the most common cause, a few cases with diltiazem10 and terazosin hydrochloride11 have been described. In a multinational case control study (EUROSCAR), which assessed the risk factors, diltiazem was found to be associated with a higher risk along with antibiotics.12 T-cell involvement is suggested by positive patch test reactions to the suspected drug.13 They may directly orchestrate a neutrophilic inflammation by releasing the neutrophil attracting chemokine CXCL8.14 Discontinuation of the drug is the only treatment necessary, although corticosteroids may be needed in some cases.

**Angioedema**

ACE inhibitors are the leading cause of drug-induced angioedema, with an incidence of 0.1–0.2%. This is non-immunological and occurs in predisposed individuals. It is caused by accumulation of vasoactive mediators like bradykinin due to reduced activity of angiotensin-converting enzyme.1 It is never accompanied by urticaria, can start years after beginning the treatment, and can recur irregularly while under treatment.15 It has varying clinical presentations including isolated involvement of lip or penis,16 one side of the tongue,17 or small bowel involvement.18 Common agents which have been implicated are enalapril,19 lisinopril20 and alacepril.21 They may also cause increased frequency, intensity and duration of bouts of idiopathic angioedema during long-term use.22,23 Icatibant, a bradykinin receptor antagonist has been shown to accelerate the resolution of ACE inhibitor induced angioedema.21 Renin inhibitor aliskerin and angiotensin receptor blockers (losartan, valsartan, candesartan) have lower risk of causing angioedema. It is less severe and occurs earlier compared to ACE inhibitors.23,24 There is less than a 10% chance for these groups of drugs to cause angioedema compared to patients who had angioedema due to ACE inhibitors.25 Angioedema has also been described in children, most commonly to the dihydropyridine group of calcium channel blockers (amlodipine and nicardipine).26

**Annular Erythema**

 Hydrochlorothiazide and spironolactone have caused erythema annulare centrifugum like eruptions.25,26

**Bullous Eruptions**

**Pseudoporphyria**

Pseudoporphyria is a porphyria like blistering on exposed areas in the absence of abnormal porphyrin metabolism. It may be caused by high dose furosemide,27 torsemide,28bumetanide,28 flutamide,29 chlorthalidone30 and dyazole (combination of triamterene and hydrochlorothiazide).31

**Pemphigus group (pemphigus foliaceus and pemphigus vulgaris)**

Drug-related pemphigus can be of two types, (i) induced pemphigus, in which exogenous factors play a major role and (ii) triggered pemphigus, in which endogenous factors play a major role. Induced pemphigus is usually caused by thiol group of drugs such as captopril. It has a long incubation period of up to one year and mostly resembles pemphigus foliaceus or pemphigus vegetans. Triggered pemphigus mimics pemphigus vulgaris, has a shorter incubation period (128 days average) and is usually caused by non-thiol drugs.33 The various non-thiol antihypertensives which trigger this are mentioned in Table 2.31,34,35,36,37 Thiol drugs provoke acantholysis in vitro possibly by increasing the activity of plasminogen activators.38 An active amide group in the molecule of non-thiol drugs may be responsible for inducing pemphigus.39

The diagnosis of drug-induced pemphigus is challenging. It resembles idiopathic pemphigus in clinical findings, histopathology and immunofluorescence, thus making it difficult to differentiate the two.40 Approximately 70–90% of patients have a positive direct immunofluorescence.41 More than half of the cases caused by thiol drugs remit following drug withdrawal, whereas only 15% of those caused by non-thiol drugs do so.33 The treatment starts with the immediate withdrawal of the suspected drug(s). Medium to high dose of systemic steroids (about 2/3 of the dose normally used in idiopathic pemphigus) is usually recommended until all symptoms of active disease disappear. In most cases, remission can be achieved within weeks, and steroid doses may be gradually tapered down to zero after a few months.42

**Drug-induced bullous pemphigoid**

Drugs may induce anti basement membrane zone antibody production by acting as hapten that bind to proteins in the lamina lucida and change their antigenic properties. They may stimulate an autoimmune response by structurally modifying molecules

---

**Table 1: Common and rare cutaneous adverse drug reactions reported with antihypertensives**

| Common | Rare |
|--------|------|
| Angioedema | Acute generalized exanthematous pustulosis |
| Bullous eruptions | Eczematous reaction |
| Pemphigus | Drug induced lichenoid eruption |
| Bullous pemphigoid | Oral and mucocutaneous ulcers |
| Pseudoporphyria | Drug reaction with cosinophilia and systemic symptoms |
| Lichenoid eruptions | Erythema multiforme |
| Photodistributed hyperpigmentation and telangiectasia | Erythema annulare centrifugum |
| Photosensitivity | Exanthematous eruption |
| Psoriasiform eruption | Erythrodema |
| Pseudolymphoma | Fixed drug eruption |
| ANCA positive vasculitis | Pityriasis rosea |
| Dry mouth | Toxic epidermal necrolysis |
| Gingival hyperplasia | Alopeica |

This list is prepared by the authors based on the current literature and available evidence. ANCA: Anti-neutrophil cytoplasmic antibody.
Thiol drugs - captopril
Non-thiol - enalapril, ramipril, fosinopril, lisinopril, cilazapril and quinapril
Others
Propranolol
Angiotensin receptor blockers - candesartan, telmisartan
Indapamide
Bullous pemphigoid
Diuretics (furosemide, bumetanide, spironolactone)
calcium channel blockers (amlodipine, nifedipine)
ACE inhibitors (captopril, enalapril, lisinopril)
Beta blockers (nadolol, practolol)
Angiotensin receptor blockers (losartan, valsartan)
Clonidine
Methyldopa
Cutaneous small vessel vasculitis
Hydralazine
Diuretics (furosemide, hydrochlorothiazide, metolozone)
Betablockers (propranolol, carvedilol, sotalol, atenolol, acebutalol)
ACE inhibitors (captopril, enalapril, ramipril)
Calcium channel blockers (amlodipine, nifedipine, diltiazem)
Angiotensin receptor blockers (losartan)
Lichenoid eruption
ACEI (captopril, enalapril, alacepril)
Beta blockers (atenolol, propranolol, labetalol, pindolol, levobunolol, metoprolol, sotalol, acebutalol, timolol eye drops, oxprenolol, nebivolol)
Diuretics (hydrochlorothiazide, furosemide, spironolactone diazoxide)
ARBs
CCBs (nifedipine, amlodipine), nicardipine, terazosin, and methyl dopa
Subacute cutaneous lupus erythematosus
Calcium channel blockers (diltiazem, verapamil, nifedipine, nitrendipine), ACE inhibitors (cilazapril, captopril, enalapril)
Thiazide diuretics (hydrochlorothiazide, triamterene)
Beta blockers (oxprenolol, acebutalol)
Pseudolymphoma
ACE inhibitors (captopril, enalapril, benazepril, lisinopril)
Calcium channel blockers (amlodipine, diltiazem, verapamil)
Beta blockers (atenolol, labetalol)
Angiotensin receptor blockers (losartan, valsartan) diuretics (hydrochlorothiazide)
Clonidine

and uncovering hidden epitopes. In drug induced bullous pemphigoid, patients tend to be younger. The clinical presentation is heterogeneous and variable. Nikolsky sign may be positive in some cases. Tissue bound and circulating anti basement membrane zone IgG antibodies may be absent. Additional antibodies such as intercellular or anti-epidermal cytoplasmatic antibodies may be detected. Histopathologically, there may be perivascular infiltration of lymphocytes with a few eosinophils and neutrophils, intraepidermal vesicles with foci of necrotic keratinocytes and thrombi in dermal vessels. Various antihypertensives can induce bullous pemphigoid (Table 2). Drugs such as furosemide and enalapril are most likely to have an association with bullous pemphigoid, proven by rechallenge. Various antihypertensives can induce bullous pemphigoid [Table 2]. Drugs such as furosemide and enalapril are most likely to have an association with bullous pemphigoid, proven by rechallenge. It can mimic other entities such as bullous erythema multiforme and pemphigus (overlapping variants). Some cases are short-lived whereas others become chronic, in the form of drug-triggered bullous pemphigoid.

Various antihypertensives can induce bullous pemphigoid ([Table 2]). Drugs such as furosemide and enalapril are most likely to have an association with bullous pemphigoid, proven by rechallenge. Bastuji-Garin et al. reported a strong association with neuroleptics and diuretics (mainly aldosterone antagonists). ACE inhibitors, anticoagulants and diuretics were found to be commonly used by patients suffering from bullous pemphigoid. In a recent case-control study that included 86 patients, loop diuretics were found to be used more frequently. This association was independent of age, cerebrovascular disease, dementia, hypertension or ischemic heart disease. Mucous membrane pemphigoid has been observed with atenolol, isolated ocular cicatricial pemphigoid with ophthalmic anti-glaucoma preparations, and anogenital cicatricial pemphigoid with clonidine. Lichen planus pemphigoides has been reported with captopril and ramipril. Its course tends to be much more indolent but it responds well to treatment. Linear IgA bullous dermatosis has been induced by captopril.

The possibility of a drug etiology must be considered in all patients suffering from bullous pemphigoid as most patients respond rapidly to treatment and do not experience relapses after the withdrawal of the suspect medication.

Cutaneous Vasculitis

Approximately 20% cases of cutaneous small vessel vasculitis are an adverse reaction to drugs and most represent hypersensitivity vasculitis. Therapeutic agents from virtually every pharmacological class have been implicated. The offending drugs can be generally categorized into: Anti-neutrophil cytoplasmatic antibody (ANCA) associated and ANCA negative group. Development of systemic vasculitis may take a few months to years following exposure. The ANCA negative group usually presents with cutaneous involvement within a few days to weeks after drug exposure. An average lag period of 28.9 days was found in an Indian study. Hydralazine has been incriminated in ANCA positive vasculitis, lupus erythematosus like syndrome and digital gangrene. Table 2 depicts the various antihypertensives that cause cutaneous small vessel vasculitis.

Blood eosinophilia is found in almost 80% patients with drug-induced systemic vasculitis. However, it is less than 25% in patients who have only cutaneous involvement. The presence of tissue eosinophilia on histology is suggestive of a drug induced vasculitis. Apart from withdrawal of the suspected drug, oral steroids may be needed in cases with systemic involvement. We need to be aware of possible cross reactions (among diuretics, calcium channel blockers) while substituting a drug.

Drug Reaction with Eosinophilia and Systemic Symptoms

This is a potentially life threatening adverse drug reaction with an estimated mortality of 10%, most commonly from fulminant hepatitis.
with hepatic necrosis. It is seen in children and adults most often as a morbilliform cutaneous eruption with fever, lymphadenopathy, hematological and multiorgan abnormalities. It has a late onset and long duration compared to other drug reactions, with a latent period of 2–6 weeks. There may be associated vesicles, bullae, atypical targetoid plaques and purpura. Sterile follicular and non-follicular pustules may be evident. The rash may progress to involve nearly the entire surface of the skin, producing an exfoliative dermatitis or erythroderma. This can be associated with mucosal involvement such as cheilitis, erosions, erythematous pharynx and enlarged tonsils.

Even though anticonvulsants, sulphonamides and allopurinol are common causes, ACE inhibitors (captopril, enalapril, ramipril), beta-blockers (atenolol, cefprozil) and spironolactone are reported to induce drug reaction with eosinophilia and systemic symptoms. Prolonged systemic corticosteroid therapy may be required. A gradual taper of this therapy over 3–6 months after clinical and laboratory stabilization is recommended to avoid relapse. Incomplete recurrences with structurally unrelated culprit drugs are a frequent phenomenon in such patients.

Erythema Multiforme
Less than 10% of cases of erythema multiforme are drug induced. Although NSAIDs, sulphonamides and antibiotics are common culprits, isolated reports have been described with furosemide, indapamide, carvedilol, metoprolol, fenoterol, nifedipine, amlodipine, diltiazem, clonidine, topical dorzolamide and candesartan axetil. It may be associated with a flu-like prodrome. Blisters and mucosal involvement is more prominent than herpes simplex virus associated erythema multiforme. The course is self limiting with no recurrences after stopping the drug. A mortality rate of 5–15% has been reported in severe cases.

Exanthenomatous Eruptions
Exanthenomatous eruptions with various morphological and localization patterns are the most frequently encountered cutaneous adverse drug reactions. They can occur after almost any drug, usually within 2-3 weeks of drug administration. They may be accompanied by fever, pruritus and eosinophilia. The course of these benign exanthems lasts for a few days to some weeks. If the drug is continued, an exfoliative dermatitis may develop. Occasionally, the eruption subsides despite continuation of the medication. Immunological effector mechanisms include drug-specific CD4+ T cells, various chemokines and cytokines. Exanthenomatous drug eruption has been reported with diltiazem and valsartan. Telmisartan has caused symmetrical drug related intertriginous and flexural exanthem.

Eczematous Eruptions
Eczematous drug reactions may be localized or generalized. The term ‘endogenous contact eczema’ refers to the occurrence of an eczematous contact drug reaction following primary sensitization by oral therapy. They may develop following therapy with methyldopa and clonidine. Among ACE inhibitors, captopril has been shown to cause an eczematous reaction, confirmed in many cases with patch testing, without any cross-reactivity with enalapril, lisinopril or benazepril. The latency period can vary from a few months to several years. A lag period of 4–30 months was observed in a study.

Eyelid dermatitis was seen with the use of beta-blocker eyedrops (timolol, befunolol, carteolol, propranolol, practalol) with cross-sensitivity among these. The proposed hypothesis of cross-sensitivity is primary metabolism of the drug to a common aldehyde. Stasis dermatitis has been described with amiodipine. Topical diltiazem used for anal fissures is known to cause contact dermatitis. In a study of 23 cases of localized and generalized eczematous drug reactions caused by antihypertensives, the class of drugs implicated were ACE inhibitors, angiotensin receptor blockers and hydrochlorothiazide in combination with ACE inhibitors or angiotensin receptor blockers. Extensive allergic contact dermatitis has been seen in factory workers coming in contact with alprenolol. Localized contact allergy with transdermal clonidine has also been described.

Eczematoid Photosensitive Reactions
Most systemic drug photosensitivity is due to phototoxic mechanisms. Different patterns of phototoxic reactions occur in the skin, including an immediate prickling/burning sensation, urticaria, sunburn-like reaction, late onset erythema, dermatitis, skin fragility and telangiectasias. Drucker and Rosen, suggested ten drugs to be considered potent photosensitizers, of which hydrochlorothiazide was the only antihypertensive. Other drugs include diuretics (triamterene, furosemide), ACE inhibitors (ramipril, enalapril, quinapril), calcium channel blockers (nifedipine), beta-blockers (timolol), angiotensin receptor blockers (valsartan), centrally acting agents (clonidine, methyldopa), valsartan and methyl-dopa have been described to cause photosensitivity in the past, but these are mostly individual case reports. Amlodipine and nifedipine can cause photodistributed facial telangiectasia. In a study of 62 cases of thiazide induced photosensitivity, eczematous presentation was found to be the most common. In most cases, phototesting revealed an abnormal response to UVA rays alone, or to both UVA and UVB. For systemic drug phototoxicity, the key investigation is phototesting with a monochromator and drug rechallenge phototesting. Photopatch testing is needed in suspected cases of photo-allergy. Drug-induced photosensitivity is usually managed by stopping the suspected drug. Other measures are sometimes necessary, including phototherapy using wavelengths that do not elicit the response.

Erythroderma
Exfoliative dermatitis is one of the most dangerous cutaneous adverse drug reactions. Captopril, lisinopril, diltiazem, amiodipine, timolol eye drops and gliceryl trinitrate have caused erythroderma. Interstitial granulomatous drug reaction secondary to enalapril presenting as erythroderma has been reported. The latency period is highly variable, ranging from a few days to several months.

Erythromelalgia
This reaction has been related to nifedipine, diltiazem, verapamil and nicardipine. It is characterized by intermittent, usually symmetrical burning pain, warmth and dermal erythema of the extremities. The symptoms are ameliorated by cooling the extremities. The time lapse between the first dose of the drug and its occurrence varied from eight weeks to a year. The time from discontinuation of the drug to resolution ranged from one to fourteen days.

Fixed Drug Eruptions
A fixed drug eruption characteristically recurs at the same site every time the drug is administered. The number of sites affected may increase with each exposure. Although this is rare following antihypertensives, diltiazem, enalapril and amiodipine have been
Implicated.\textsuperscript{109} Isolated reports of fixed drug eruption secondary to propranolol,\textsuperscript{110} atenolol,\textsuperscript{111} bisoprolol, nifedipine,\textsuperscript{112} hydralazine\textsuperscript{113} and indapamide\textsuperscript{114} have been described. The latency period was 2 months to 19.6 months in an Indian study.\textsuperscript{2}

**Hyperpigmentation**

Diltiazem has been implicated as the cause of photodistributed hyperpigmentation in several reports. The interval from initiation of diltiazem to the onset varies from a few months to years. Histologically, the changes are consistent with a lichenoid dermatitis that show basal vacuolar alteration and prominent pigment incontinence.\textsuperscript{100,108,115} Kubo et al. propose that diltiazem associated photodistributed hyperpigmentation must be a specific type of drug-induced photosensitive lichenoid eruption, probably in the UVB range.\textsuperscript{116} Photoprotection, hydroquinone and tacrolimus cream have been tried. Pigmentation of skin predominantly over sun-exposed areas and pigmentation of oral mucosa have been described after one year of amiodipine intake.\textsuperscript{117}

**Lichenoid Drug Eruptions**

Lichenoid drug eruptions tend to be extensive and may develop weeks or months after initiation of therapy [Figure 1]. Lesions may be more psoriasiform than those seen in classic lichen planus. Oral involvement is rare. There may be atypical features such as marked scaling, eczematization, hypertrophic lesions and a tendency to more intense residual hyperpigmentation.\textsuperscript{118} The antihypertensives which may cause lichenoid drug eruption are enumerated in Table 2.\textsuperscript{119-124} Cross-reactivity among beta-blockers has not been demonstrated.\textsuperscript{121} Valsartan caused linear lichenoid eruption\textsuperscript{122}, whereas lichenoid nail dystrophy was reported to angiotensin receptor blockers in another case.\textsuperscript{125} Bullous lesions were seen with labetalol, and penile involvement with propranolol.\textsuperscript{126} Photolichenoid eruption has been reported with hydrochlorothiazide, enalapril\textsuperscript{119} and inhaled tiotropium bromide.\textsuperscript{127} Isolated oral eruptions have been seen with calcium channel blockers, ACE inhibitors and beta-blockers.\textsuperscript{128} Oral ulcerative lichen planus was observed with methyldopa.\textsuperscript{129} The intra-oral sites of predilection include the posterior buccal mucosa, tongue, floor of mouth, palate and alveolar ridges. There appears to be a preference for unilateral distribution. They are nearly identical to oral lichen planus clinically, histologically and immunologically.\textsuperscript{130} McCartan and McCreary have provided a structured system for reporting oral lichenoid drug eruption cases.\textsuperscript{131}

![Figure 1: Lichenoid papules and plaques over the dorsal aspect of both hands](image)

The lag period is variable and the latency period ranges from one month to two years (19.6 months average). Resolution of the skin and mucosal eruptions may be slow and variable, with a resolution time of 1–4 months.\textsuperscript{2} Withdrawal of the drug and symptomatic treatment is often sufficient. Severe cases may require corticosteroid therapy as in idiopathic lichen planus.

**Lupus Erythematosus**

Drug-induced lupus erythematosus is defined as a lupus erythematous like syndrome temporally related to continuous drug exposure, which resolves after discontinuation of the offending drug. Similar to idiopathic lupus erythematosus, this can be divided into systemic lupus erythematosus (SLE), subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus.\textsuperscript{132} It is believed that Fas-dependent apoptosis of epidermal basal keratinocytes plays an important role. A reduction of immunohistochemical expression of Bcl-2, an antiapoptotic protein, has been demonstrated in lesional skin along the epidermal basal layer among such patients.\textsuperscript{133} In general, old patients are affected and there is no sex predilection as seen in idiopathic SLE. The time between drug exposure to onset of symptoms varies from a month to more than a decade.\textsuperscript{134}

Skin involvement is less frequent in drug-induced SLE, although its exact incidence remains controversial. Certain non-specific cutaneous manifestations such as purpura, erythema nodosum and photosensitivity are frequently present in drug-induced SLE than its idiopathic counterpart. Features such as malar rash, discoid lesions, mucosal ulcers, alopecia and Raynaud’s phenomenon are usually absent in drug-induced SLE. Other non-specific features such as urticaria, urticarial vasculitis and signs of necrotising vasculitis may be considered characteristic of drug-induced lupus erythematosus.\textsuperscript{132,134,135} Fever, arthralgia, myalgia, pleurisy and pericarditis are present, whereas renal and central nervous system involvement is rare. Anti-nuclear antibody and anti-histone antibodies are positive, whereas Anti-ds DNA is usually negative and complement levels are normal. Deposition of immunoreactants in uninvolved skin is rare. A negative ANA test should not automatically preclude a diagnosis of drug-induced lupus erythematosus, particularly if the patient has other autoantibodies associated with SLE or drug-induced lupus erythematosus.\textsuperscript{132,134} Hydralazine induced lupus erythematosus with Sweet’s syndrome has been reported.\textsuperscript{136}

Of the antihypertensives implicated in drug-induced SLE [Table 2],\textsuperscript{132,134} hydralazine and methyldopa have a definite association while others have a probable or possible association.\textsuperscript{137} A matched, nested, case-control study conducted in the United Kingdom to investigate drugs causing lupus erythematosus found a causal relationship only for carbamazepine, minocycline and possibly hydralazine.\textsuperscript{138} Resolution or marked improvement of the symptoms generally occurs within 2–5 weeks of drug withdrawal, although some patients may require NSAIDS or low dose systemic steroids. Immunosuppressive drugs may be needed in severe cases with renal or neurological involvement. Patients who develop ANA positivity during treatment need not have the drug stopped. They do not require treatment unless they have clinical features of lupus erythematosus.\textsuperscript{138} Drug-induced subacute lupus erythematosus [Table 2]\textsuperscript{132,134} is similar to its idiopathic counterpart, both clinically and serologically.\textsuperscript{134,136} In most cases, there is spontaneous resolution within weeks of drug withdrawal. The Anti Ro/SS-A antibodies may remain positive even after resolution of disease activity.\textsuperscript{140}
**Pityriasis Rosea-Like Eruptions**

An Italian series reported cases of pityriasis rosea linked to ACE inhibitors, alone or in combination with hydrochlorothiazide. They had also reported a case of pityriasis rosea with hydrochlorothiazide plus losartan.141

**Palmoplantar Keratoderma**

Losartan has been shown to cause palmoplantar hyperkeratosis, which resolved after withdrawal of the drug.142

**Psoriasiform Eruptions**

The antihypertensives that are strongly related to psoriasis are beta blockers and ACE inhibitors. Other drugs also have been reported to induce or aggravate psoriasis, but the evidence is less strong. In general, most drugs tend to exacerbate psoriasis rather than induce it.146 Drug-induced psoriasiform eruption tends to occur de novo in patients with no prior personal or family history of psoriasis.147 The eruptions appear 1–18 months after initiation of the drugs.148 However, a lag period of two years has been observed.149 Psoriasiform eruptions clear after several weeks of drug withdrawal,149 but drug aggravated psoriasis may not completely. Drug-induced psoriasiform eruption is not true psoriasis. The lesions are less red, less thick and less scaly. Histopathologically, they lack neutrophils or Munro’s microabscesses. Both cardioselective and non-cardioselective beta blockers can aggravate psoriasis or induce a psoriasiform rash.149 Topical application of timolol in the treatment of open angle glaucoma has been reported to induce psoriasis and transform psoriasis vulgaris into psoriatic erythroderma, by systemic absorption via the conjunctiva.150

Blockade of beta 2 receptors leads to a decrease of cAMP, causing a decrease in intracellular calcium, excessive release of enzymes by lymphocytes, neutrophils and macrophages. This consequently increases cellular proliferation and lack of differentiation.151 ACE inhibitors have been implicated in case-control and case-crossover studies.146,151 They act by altering the kinin-kallikrein arachidonic acid system, which may lead to increased concentrations of inflammatory metabolites, thus inducing psoriasis. Other drugs with a weak association include angiotensin receptor blockers,152 calcium channel blockers,153 clonidine154 and urapidil (α1 adrenergic blocker).155

A prospective cohort study on the risk of psoriasis taking individual antihypertensives found that only beta blockers were associated with an increased risk after regular use for six or more years.156 On the other hand, in a population based case-control study, no increased or altered risk of psoriasis was found with beta blockers or other antihypertensives.157 Propranolol,158 atenolol,159 pindolol,2 ramipril160 and candesartan160 have been shown to induce generalized pustular psoriasis. Captopril, enalapril and perindopril have caused palmoplantar psoriasis and palmoplantar pustulosis.162 Oxprenolol has been shown to exacerbate psoriatic arthropathy.163 Diltiazem has also precipitated psoriatic erythroderma.164

**Pseudolymphomatous Drug Eruptions**

Cutaneous pseudolymphomas can be either of T-cell or B-cell origin on histology. Characteristically, anticonvulsant induced pseudolymphoma hypersensitivity syndromes develop soon after the drug has been started, usually within two to eight weeks.165 However, cases have developed as late as seven years.166 There are numerous reports of antihypertensive induced pseudolymphomatous drug eruptions in the literature [Table 2].167–175 They resolve in 1–32 weeks of discontinuing the medication.175 It is postulated that the drug may promote an aberrant immune response to an antigen, which may be the drug itself, or some other stimulus. Failure of lesions to resolve months after drug discontinuation should raise suspicion of a malignant process. Appropriate investigations must be done, as true lymphomas may occasionally develop.

**Toxic Epidermal Necrolysis**

Although antihypertensive associated toxic epidermal necrolysis is extremely rare, isolated reports secondary to sodium nitroprusside,176 amiodipine,177 captopril,179 carvedilol,179 oral minoxidil,180 indapamide,181 alfuzosin182 and hydrochlorothazine have been described. Timolol, dalfuzomide, and latanoprost eye drops183 may also induce this condition. A multinational case-control study conducted in Europe found that beta blockers, ACE inhibitors, calcium channel blockers, thiazide diuretics and furosemide were not associated with a detectable risk of Stevens Johnson syndrome or toxic epidermal necrolysis.185 A similar result was found for thiazides186 and ACE inhibitors.187

**Hair and Nail Changes**

Propranolol,188 metoprolol189 and certain ophthalmic beta blockers186 can cause alopecia. Diazoxide and minoxidil can cause hypertrichosis.191 Drug-induced changes in hair colour, usually occurs 3–12 months after the onset of treatment,192 and has been described with verapamil.193 Onycholysis may occur with captopril, thiazides, proctalol and indapamide.194

**Oral Changes**

Dry mouth has been reported in approximately 20% of hypertensives treated with beta-adrenergic blockers. They may decrease the total
protein content of saliva. The administration of ACE inhibitors may cause dry mouth due to reduction of the salivary flow rate. Diuretics may cause dry mouth by dehydration and salivary gland hypofunction. Alpha 1 adrenergic agents may result in altered saliva composition and secretion rates. Dry mouth is reversible on drug discontinuation.

ACE inhibitors are associated with taste disturbances. Impaired or salty taste is a frequent complaint with captopril. These tend to be self limiting and reversible within two to three months even if the drug is continued. Malic acid 1% spray improved antihypertensive induced xerostomia and stimulated the production of saliva. Buccal ulceration and aphthous-like ulcers have been reported with beta blockers, ACE inhibitors (captopril, enalapril), angiotensin receptor blockers (losartan), nicorandil and methyldopa. Nicorandil can cause oral, anal and mucocutaneous ulcerations. It may rarely cause leg ulceration without mucosal involvement. Within the calcium channel blockers family, nifedipine, diltiazem, verapamil and amiodipine can cause gingival hyperplasia. Tissue enlargement typically occurs within one to three months of therapy, usually beginning in the interdental papillae. Its pathogenesis is traced back to the increased production of collagen by gingival fibroblasts, which may account for the lack of rapid resolution after drug discontinuation.

Diagnosis of Cutaneous Adverse Drug Reactions to Antihypertensive Drugs

Numerous methods for causality assessment in adverse drug reactions have been published. They fall into three broad categories – expert judgement, algorithms and probabilistic methods. Due to problems of reproducibility and validity, no single method is universally accepted. At present there are no specific tests that can predict the capacity of drugs to induce allergic reactions, or of the susceptibility of individuals to experience an allergic reaction. Skin testing, especially patch test, was found to be a useful screening method if the reaction was exanthema. It was also useful if antimicrobial, cardiovascular or antiepileptic drugs were suspected. Oral rechallenge needs to be considered when patch tests are negative, but cannot be performed in case of severe drug reactions. As the latency of the reaction is prolonged and variable with many antihypertensives, the utility of an oral rechallenge in such situations is doubtful. In-vitro cytokine release tests like interferon gamma release test and the cell scan apparatus to detect such situations is doubtful. In-vitro methods. Due to problems of reproducibility and validity, no single method is universally accepted. At present there are no specific tests that can predict the capacity of drugs to induce allergic reactions, or of the susceptibility of individuals to experience an allergic reaction. Skin testing, especially patch test, was found to be a useful screening method if the reaction was exanthema. It was also useful if antimicrobial, cardiovascular or antiepileptic drugs were suspected. Oral rechallenge needs to be considered when patch tests are negative, but cannot be performed in case of severe drug reactions. As the latency of the reaction is prolonged and variable with many antihypertensives, the utility of an oral rechallenge in such situations is doubtful. In-vitro cytokine release tests like interferon gamma release test and the cell scan apparatus to detect activation of lymphocytes may have a role in diagnosing cutaneous drug eruptions in the future.

Conclusion

Cutaneous adverse drug reactions to antihypertensives are common. The time of onset and presentation is highly variable. Hypertensive patients are receiving multiple drug therapy nowadays, more than what used to be the norm a decade ago. The ever increasing list of newer antihypertensives has contributed to a substantial increase in the number of adverse reactions, especially cutaneous. Hence, dermatologists need to be aware of the various antihypertensives and the cutaneous adverse drug reactions that can occur due to them. Large scale population based prospective studies might give us further insights into the frequency, as well as the clinical presentations that can be expected. Further studies are necessary on tests for causality assessment of such reactions.

Financial support and sponsorship

Nil. No financial support or sponsorship has been received.

Conflicts of interest

There are no conflicts of interest.

References

1. Turk BG, Gunaydin A, Ertam I, Ozturk G. Adverse cutaneous drug reactions among hospitalised patients: Five year surveillance. Cutan Ocul Toxicol 2013;32:41-5.
2. Upadhyay JB, Nangia AK, Mukhija RD, Misra M, Mohan L, Singh KK. Cutaneous reactions due to antihypertensive drugs. Indian J Dermatol 2006;51:189-91.
3. Thesstrup-Pedersen K. Adverse reactions in the skin from anti-hypertensive drugs. Dan Med Bull 1987;34 Suppl 1:3-5.
4. Steckelings UM, Artuc M, Wollschlager T, Wieberts S, Henz BM. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol 2001;81:321-5.
5. Ioulis P, Charalampous M, Efrossini T. The spectrum of cutaneous reactions associated with calcium antagonists: A review of the literature and the possible etiopathogenic mechanisms. Dermatol Online J 2003;9:6.
6. Tuchinda P, Kultahanan K, Khankham S, Jongjarearnprasert K, Dhana N. Cutaneous adverse reactions to calcium channel blockers. Asian Pac J Allergy Immunol 2014;32:246-50.
7. Faure M, Hermier C, Perrot H. Cutaneous reactions to propanolol (author’s transl). Ann Dermatol Venereol 1979;106:161-5.
8. Bonnetblanche JM. Drug eruptions caused by beta-blockers. Ann Med Interne (Paris) 1984;135:639-41.
9. Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol 2015;73:843-8.
10. Serrota V, Caldas Lopes L, Campos Lopes JM, Lobo L, Ferreira A. Acute generalized exanthematous pustulosis associated with diltiazem. Acta Med Port 2008;21:99-102.
11. Speck LM, Wilkerson MG, Perri AJ, Kelly BC. Acute generalized exanthematous pustulosis caused by terazosin hydrochloride. J Drugs Dermatol 2008;7:395-7.
12. Gensch K, Hodziec-Avdagic N, Megahed M, Ruzicka T, Kuhn A. Acute generalized exanthematous pustulosis with confirmed type IV allergy. Report of 3 cases. Hautarzt 2007;58:250-2, 254-5.
13. Britschgi M, Pichler WJ. Acute generalized exanthematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2002;2:325-31.
14. Sidoroff A, Dunant A, Viboud C, Haley S, Bainvjin NC, Naldi L, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007;157:989-96.
15. Inomata N. Recent advances in drug-induced angioedema. Allergol Int 2012;61:545-7.
16. Miller DG, Swies RT, Toerne TS. Penile angioedema developing after 3 years of ACEI therapy. J Emerg Med 2012;43:273-5.
17. Leung E, Hanna MY, Tehani N, Francombe J. Isolated unilateral tongue oedema: the adverse effect of angiotensin converting enzyme inhibitors. Curr Drug Saf 2012;7:382-3.
18. Smet BS, De Kock I, De Backer AI, Verstraete K. Angioedema of the small bowel caused by angiotensin converting enzyme inhibitor. JBR BTR 2013;96:41.
19. Katoh H, Itagaki T, Suzuki K, Obata Y, Adachi Y, Doi M, et al. Successful extubation in a patient with alacepril-induced tongue angioedema. Masui 2010;59:519-22.
20. Kozel MM, Mekkes JR, Bos JD. Increased frequency and severity of angio-oedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients. Clin Exp Dermatol 1995;20:60-1.
21. Gallitelli M, Alzetta M. Itchibant: a novel approach to the treatment of angioedema related to the use of angiotensin-converting enzyme inhibitors. Am J Emerg Med 2012;30:1664.e1-2.
22. Toh S, Reichman ME, Houston M, Ross Southworth M, Ding X.
Hernandez AF, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012;172:1582-9.

23. Beavers CJ, Dunn SP, Macaulay TE. The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedema. Ann Pharmacother 2011;45:520-4.

24. Pierce WA, Hederman AD, Gordon CJ, Ostrenga AR, Harrington B. Angioedema associated with dihydropyridine calcium-channel blockers in a child with Burkitt lymphoma. Am J Health Syst Pharm 2011;68:402-6.

25. Goette DK, Beatrice E. Erythema annulaire centrifugum caused by hydrochlorothiazide-induced interstitial nephritis. Int J Dermatol 1988;27:129-30.

26. Carsuzaa F, Pierre C, Dubegny M. Erythema annulaire centrifugum caused by aldactone. Ann Dermatol Venereol 1987;114:375-6.

27. Breier F, Feldmann R, Pelzl M, Gschnait F. Pseudoporphyria cutanea tarda induced by furosemide in a patient undergoing peritoneal dialysis. Dermatology 1998;197:271-3.

28. Pérez-Bustillo A, Sánchez-Sambucety P, Suárez-Amor O, Rodriguez-Prieto MA. Torsemide-induced pseudoporphyria. Arch Dermatol 2008;144:812-3.

29. Leitao EA, Person JR. Bumetanide-induced pseudoporphyria. J Am Acad Dermatol 1990;23:129-30.

30. Schmutz JL, Barbaud A, Tréchot P. Flutamide and pseudoporphyria. Br J Dermatol 1989;120:406.

31. Baker EJ, Reed KD, Dixon SL. Chlorthalidone-induced pseudoporphyria: clinical and microscopic findings of a case. J Am Acad Dermatol 1989;21 (5 Pt 1):1026-9.

32. Motley RJ. Pseudoporphyria due to dyazide in a patient with vitiligo. BMJ 1990;300:1468.

33. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol 1998;16:393-7.

34. Ong CS, Cook N, Lee S. Drug-related pemphigus and angiotensin converting enzyme inhibitors. Australas J Dermatol 2000;41:242-6.

35. Patterson CR, Davies MG. Pemphigus foliaceus: an adverse reaction to lisinopril. J Dermatol Treat 2001;12:175-7.

36. Godard W, Lambert D, Gavanou J, Chapuis JL. Pemphigus induced by treatment with a propanolol-meprobamate combination. Ann Dermatol Venereol 1980;107:1213-6.

37. Bae YI, Yun SJ, Lee SC, Park GT, Lee JB. Pemphigus foliaceus induced by an angiotensin II receptor blocker. Clin Exp Dermatol 2008;33:723-31.

38. Bayramgürler D, Erçin C, Apaydin R, Unal G. Indapamide-induced pemphigus. Dermatologica 1991;182:207‑10.

39. Lombardi ML, de Angelis E, Rossano F, Ruocco V. Imbalance between proinflammatory and anti-inflammatory factors: facts and controversies. Clin Dermatol 2013;31:391-9.

40. Liu HN, Su WP, Rogers RS 3rd. Clinical variants of pemphigoid. Int J Dermatol 1986;25:17-27.

41. Park KY, Kim BJ, Kim MN. Amlodipine-associated bullous pemphigoid with erythema multiforme-like clinical features. Int J Dermatol 2011;50:637-9.

42. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigus: a review of the literature. J Eur Acad Dermatol Venereol 2014;28:1133-40.

43. Femiao F. Mucocutaneous bullous pemphigoid induced by valsartan. A clinical case. Minerva Stomatol 2003;52:187-90.

44. Bastuji-Garin S, Joly P, Picard-Dahan C, Bernard P, Vaillant L, Pouwels C, et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 1996;132:272-6.

45. Patatsis A, Vyzantiadis TA, Chrysovalallis F, Devliotou-Panagiotidou D, Sotiriadis D. Medication history of a series of patients with bullous pemphigoid from Northern Greece—observations and discussion. Int J Dermatol 2009;48:132-5.

46. Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol 2013;149:58-62.

47. Kanjanabuch P, Arporniam S, Thamrat S, Thumasombut P. Mucous membrane pemphigoid in a patient with hypertension treated with atenolol: a case report. J Med Case Rep 2012;6:373.52. Kubo M, Sakuraba T, Arai Y, Nakazawa M. A case of suspected drug-induced ocular pemphigoid. Nippon Ganka Gakkai Zasshi 2001;105:189-92.

48. van Joost T, Faber WR, Manuel HR. Drug-induced unoganol citrachial pemphigoid. Br J Dermatol 1980;102:715-8.

49. Harting MS, Hsu S. Lichen planus pemphigoides: a case report and review of the literature. Dermatol Online J 2006;12:10.

50. Friedman IS, Rudikoff D, Phelps RG, Sapadin AN. Captopril-triggered linear IgA bullous dermatosis. Int J Dermatol 1998;37:608-12.

51. Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008;9:71-92.

52. ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002;36:130-47.

53. Yokogawa N, Vivoín FB. Hyaluradine-induced autoimmune disease; comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol 2009;19:338-47.

54. Pulido-Pérez A, Avilés-Izquierdo JA, Suárez-Fernández R. Cutaneous vasculitis. Actas Dermosifiliogr 2012;103:179-91.

55. Pavlovic MD, Dragojevic Simic V, Zolotarevski L, Zecevic RD, Vesic S. Cutaneous vasculitis induced by carvedilol. J Eur Acad Dermatol Venereol 2007;21:1004-5.

56. Miralles R, Pedro-Botet J, Farré M, Rubiés-Prat J. Captopril and vasculitis. Ann Intern Med 1988;109:514.

57. Carrington PR, Sanusi JD, Zarrhada S, Winder PR. Enalapril-associated erythema and vasculitis. Cutis 1993;51:121-3.

58. Gupta S, Gandhi NM, Ferguson J. Cutaneous vasculitis secondary to ramipril. J Drugs Dermatol 2004;3:81-2.

59. Meissner K, Kaufmann R. Annular leukocytoclastic vasculitis after the administration of an amlodipine generic. J Eur Acad Dermatol Venereol 2009;23:238-9.

60. Kuo M, Winiarski N, Garella S. Nonthrombocytopenic purpura associated sequentially with nifedipine and diltiazem. Ann Pharmacother 1992;26:1089-90.

61. Piéard Franchimont C, Henry F, Piéard GE. Severe purpural and polymorphous vasculitis caused by loxartan. Ann Dermatol Venereol 2001;128(10 Pt 1):1040-2.

62. Bahrami S, Malone JC, Webb KG, Callen JP. Tissue eosinophilia as an indicator of drug-induced cutaneous small-vessel vasculitis. Arch Dermatol 2006;142:155-61.

63. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: Part I. Clinical perspectives. J Am Acad Dermatol 2013;68:693.e1-14.

64. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-7.

65. Li ema H, Lei SH, Merino R, Gonzalez-Obeso E, et al. DRESS-syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpesvirus 6 in an 11-year-old Caucasian boy. J Clin Pharmacol Ther 2010;35:365-70.

66. Pileri A, Brunasso AM, Tizl H, Wolf P, Massone C. Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol 2011;21:624-5.

67. Ghislain PD, Bodarwe AD, Vannerson O, Tennenst C, Maret M, Lachappe JM. Drug-induced eosinophilia and multisystemic failure with positive patch-test reaction to spirinolactone: DRESS syndrome. Acta Derm Venereol 2004;84:65-8.

68. Spriet S, Banks TA. Drug reaction with eosinophilia and systemic symptoms syndrome. Allergy Asthma Proc 2015;36:501-5.

69. Picard D, Vella M, Janela B, Roussel A, Joly P, Musette P. Recurrence of drug-induced reactions in DRESS patients. J Eur Acad Dermatol Venereol 2015;29:801-4.

70. Samim F, Auluck A, Zed C, Williams PM. Erythema multiforme: a
review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin North Am 2013;57:583-96.
76. Zugermaier C, La Voo EJ. Erythema multiforme caused by oral furosemide. Arch Dermatol 1980;116:518-9.
77. Gales BJ, Gales MA. Erythema multiforme and angioedema with indapamide and sertraline. Am J Hosp Pharm 1994;51:118-9.
78. Hong JA, Bisognano JD. Metoprolol succinate therapy associated with erythema multiforme. Cardiol J 2009;16:82-3.
79. Sachs B, Renn C, al Masauoudi T, Merk HF. Fenoterol-induced erythema exudativum multiforme-like exanthem: demonstration of drug-specific lymphocyte reactivity in vivo and in vitro. Acta Derm Venereol 2001;81:368-9.
80. Springuel P. Erythema multiforme and nifedipine. CMAJ 1997;156:90-1.
81. Bewley AP, Feher MD, Staughton RC. Erythema multiforme following captopril. J Am Acad Dermatol 1999;40:95-100.
82. Munshi V, Abluvalia H. Erythema multiforme after use of topical amlopidine for nifedipine. BMJ 1993;307:241.
83. Berbis P, Alfonso MJ, Levy JL, Privat Y. Diltiazem associated erythema. Immunopharmacol Immunotoxicol 2013;35:447-50.
84. Schoele T, Trechot P, Schmutz JL, Faure G, Bene MC, Barbuda A. Maculopapular rash induced by diltiazem: allergological investigations in four patients and cross reactions between calcium channel blockers. Allergy 2003;58:1207-9.
85. Ekenvall L, Forsbeck M. Contact eczema produced by a beta-adrenergic receptor blocker. Allergy 1995;50:255-60.
86. Yawalkar N. Drug-induced exanthems. Toxicology 2005;209:131-4.
87. Bircher AJ. Uncomplicated drug-induced exanthemas. Clin Exp Dermatol 2005;30:293-5.
88. Ozturk G, Turk BG, Senturk B, Turkmen M, Kandiloglu G. Exanthematous drug eruption due to valsartan. Cutan Ocul Toxicol 2012;31:335-7.
89. Gómez-Bernal S, Álvarez-Pérez A, Rodríguez-Pazos L, Gutiérrez-González E, Rodríguez-Granados MT, Toribio J. Photosensitive lichenoid eruption and inhaled tiotropium bromide. Dermatol Clin 2014;32:363-8.
90. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf 2011;34:821-37.
91. Gómez-Bernal S, Álvarez-Pérez A, Rodríguez-Pazos L, Gutiérrez-González E, Rodríguez-Granados MT, Toribio J. Photosensitivity due to thiazides. Actas Dermosifiliogr 2014;105:569-76.
92. O’Neill PG, Rajan N, Charlat ML, Bolli R. Captopril-related exfoliative dermatitis. Tex Med 1989;85:40-1.
93. Vena GA, Cassano N, Coco V, De Simone C. Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Immunopharmacol Immunotoxicol 2013;35:447-50.
94. Okumura T, Takayama A. Erythema multiforme caused by a beta-blocker (timolol maleate) eyedrops. J Am Acad Dermatol 1997;37(5 Pt 1):799-800.
95. Ryan FP. Erythrodermia due to periparin and glyceryl trinitrate. Br J Dermatol 1972;87:498-500.
96. Leinonen PT, Riekki R, Oikarinen A. Contact allergy to diltiazem. Contact Dermatitis 2001;83:368-9.
97. Ekenvall L, Forsbeck M. Contact eczema produced by a beta-adrenergic receptor blocker. Allergy 1995;50:255-60.
98. Bircher AJ. Uncomplicated drug-induced exanthemas. Toxicology 2005;209:131-4.
99. Berbis P, Alfonso MJ, Levy JL, Privat Y. Diltiazem associated erythema. Immunopharmacol Immunotoxicol 2013;35:447-50.
100. Gómez-Bernal S, Álvarez-Pérez A, Rodríguez-Pazos L, Gutiérrez-González E, Rodríguez-Granados MT, Toribio J. Photosensitivity due to thiazides. Actas Dermosifiliogr 2014;105:569-76.
101. O’Neill PG, Rajan N, Charlat ML, Bolli R. Captopril-related exfoliative dermatitis. Tex Med 1989;85:40-1.
Cutaneous adverse reactions to antihypertensives

131. McCartan BE, McCreary CE. Oral lichenoid drug eruptions. Oral Dis 1997;3:58-63.
132. Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus 2009;18:935-40.
133. Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 2001;144:958-66.
134. Vasos S. Drug-induced lupus: an update. Lupus 2006;15:757-61.
135. Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res 2009;301:99-105.
136. Cartee TV, Chen SC. Sweet syndrome associated with hydralazine-induced lupus erythematosus. Curr Dis 2012;89:121-4.
137. Sruay-Puttini P, Appositi F, Capsoni F, Lubrano E, Doria A. Drug-induced lupus erythematosus. Autoimmunity 2005;38:507-18.
138. Schoonen WM, Thomas SL, Somers EC, Smeeth L, Kim J, Evans S, et al. Do selected drugs increase the risk of lupus? A matched case-control study. Br J Clin Pharmacol 2010;70:588-96.
139. Aguirre Zamorano MA, Lopez Pedrera R, Cuadrado Lozano MJ. Drug-induced lupus. Med Clin (Barc) 2010;135:124-9.
140. Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD. A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 2011;164:465-72.
141. Atzori L, Pinna AL, Ferrel C, Aste N. Pyripyzis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center. Dermatol Online J 2006;12:1.
142. Calvo M, Fernandez-Guarino M, Martin-Saez E, Carrillo R. Drug-induced lupus erythematosus during clonidine therapy. J Invest Dermatol 1988;127:619-27.
143. Vitale E, Sallustio A, Spinazzola A. Drug-induced lupus erythematosus. Dermosifiliogr 2006;97:463-6.
144. Sardana K, Sarkar R, Sehgal VN. Pigmented purpuric dermatoses: an overview. Int J Dermatol 2004;43:482-8.
145. Ball P. Thrombocytopenia and purpura in patients receiving chlorothiazide and hydrochlorothiazide. J Am Med Assoc 1960;173:665-9.
146. Foti C, Carbonara AM, Guida S, Antelmi A, Mazzocca A, Romita P, et al. Frictional purpuric eruption associated with angiotensin II receptor blockers. Dermatol Ther 2014;27:97-100.
147. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007;25:606-15.
148. Heng MC, Heng MK. Beta-adrenoceptor antagonist-induced psoriasis. Clinical and pathogenetic aspects. Int J Dermatol 1988;27:619-27.
149. Puig L, Goñi FJ, Roqué AM, Bordas FD, de Moragas JM. Psoriasis provoked by propranolol. Arch Dermatol 1985;121:1326-7.
150. Wakefield PE, Berger TG, James WD. Atenolol-induced purpural psoriasis. Arch Dermatol 1990;126:968-9.
151. Thakor P, Padmanabhan M, Johnson A, Pararajasingam T, Thakor S, Jorgensen W. Ramipril-induced generalized purpuric psoriasis: case report and literature review. Am J Ther 2010;17:92-5.
152. Kawamura A, Ochiai T. Candesartan cilexetil induced purpuric psoriasis. Eur J Dermatol 2003;13:406-7.
153. Eriksen JG, Christiansen JJ, Asmussen Jr. Postulosis palmoplantaris caused by angiotensin-converting enzyme inhibitors. Ugeskr Laeger 1995;157:3335-6.
154. Macfarlane DG, Settas L. Acute psoriatic arthropathy precipitated by oxprenolol. Ann Rheum Dis 1984;43:102-4.
155. Larivière AP, Van Dijcke C, Vermeer BJ. Diltiazem-associated exfoliative dermatitis in a patient with psoriasis. Acta Derm Venerol 1986;66:536-8.
156. Kardaun SH, Scheffer E, Vermeer BJ. Drug-induced pseudolymphomatous skin reactions. Br J Dermatol 1988;118:545-52.
157. Wood GS, Tung RM, Haefliger AC, Crooks CF, Liao S, Orozco R, et al. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sezary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGE). J Invest Dermatol 1994;103:34-41.
158. Furness PN, Goodfield MJ, MacLennan KA, Stevens A, Millard LG. Severe cutaneous reactions to captopril and enalapril: histological study and comparison with early mycosis fungoides. J Clin Pathol 1986;39:902-7.
159. Kabashima R, Orimo H, Hino N, Nakashima D, Kabashima K, Tokura Y. CD30-positive T-cell pseudolymphoma induced by amiodipine. J Eur Acad Dermatol Venereol 2008;22:1522-4.
160. Ploysangam T, Breneman DL, Mutamin DF. Cutaneous pseudolymphomas. J Am Acad Dermatol 1998;38 (6 Pt 1):877-95.
161. Henderson CA, Shamy HK. Atenolol-induced pseudolymphoma. Clin Exp Dermatol 1990;15:119-20.
162. Viraben R, Lamant L, Brouset P. Losartan-associated atypical cutaneous lymphoid hyperplasia. Lancet 1997;350:1366.
163. Sawada Y, Yoshiki R, Kawakami C, Fukamachi S, Sugita K, Nakamura M, et al. Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption. Acta Derm Venereol 2010;90:521-2.
164. Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series. Cancer 2013;119:825-31.
165. Shelley WB, Shelley ED. Pseudolymphoma at site of clindamycin patch. Lancet 1997;350:1223-4.
166. Magro CM, Crowson AN. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis. Hum Pathol 1996;27:125-32.
167. Kilic M, Ozturk F, Genc G, Guner SN, Yildiz L, Sancak R. Sodium nitroprusside and toxic epidermal necrolysis. Asian Pac J Allergy Immunol 2012;30:243-5.
168. Baetz BE, Patton ML, Guilday RE, Reigart CL, Ackerman BH. Amlodipine-induced toxic epidermal necrolysis. J Burn Care Res 2011;32:158-60.
169. Alkurtass DA, Al-Jazairi AS. Possible captopril-induced toxic epidermal necrolysis. Ann Pharmacother 2003;37:380-3.
170. Vlahovic-Palcevski V, Milic S, Hauser G, Petric A, Zupan Z, Reljic M, et al. Toxic epidermal necrolysis associated with carvedilol treatment. Int J Clin Pharmacol Ther 2010;48:549-51.
171. Kardaun SH, Scheffer E, Vermeer BJ. Diltiazem-associated toxic epidermal necrolysis. Ann Rheum Dis 1994;53:92-5.
172. Partanen J, Polhjola-Sintonen S, Mäki-Järvi M, Härma M. Toxic epidermal necrolysis due to indapamide. Arch Dermatol 1993;129:793.
173. Wang YS, Tay YK, Kwock C. Toxic epidermal necrolysis caused by alfuzosin, an alpha-1-adrenoceptor antagonist. Arch Dermatol 2006;142:938.
174. Chan JC, Yap DY, Yeung CK. Hyaluridine-induced toxic epidermal necrosis in a patient on continuous ambulatory peritoneal dialysis. J Clin Pharm Ther 2014;39:322-4.
175. Flórez A, Rosón E, Conde A, González B, García-Doval I, de la Torre C, et al. Toxic epidermal necrolysis secondary to timolol, dorzolamide,
and latanoprost eyedrops. J Am Acad Dermatol 2005;53:909-11.

185. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Haley S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44.

186. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.

187. Rzany B, Mockenhaupt M, Norbert Hollander N, Zobel K, Stocker U, Schröder W, et al. Very low risk for ace-inhibitors associated with Stevens-Johnson syndrome and toxic epidermal necrolysis based on prescription data in defined daily doses. J Invest Dermatol 1994;102:619.

188. England JR, England JD. Alopecia and propranolol therapy. Aust Fam Physician 1982;11:225-6.

189. Graeber CW, Lapkin RA. Metoprolol and alopecia. Cutis 1981;28:633-4.

190. Fraunfelder FT, Meyer SM, Menacker SJ. Alopecia possibly secondary to topical ophthalmic beta-blockers. JAMA 1990;263:1493-4.

191. Parker LN, Lifrak ET, Odell WD. Lack of a gonadal or adrenal androgenic mechanism for the hypertrichosis produced by diazoxide, phenytoin and minoxidil. Biochem Pharmacol 1982;31:1948-50.

192. Publin JG, Thompson DF. Drug-induced hair colour changes. J Clin Pharm Ther 1992;17:297-302.

193. Read GM. Verapamil and hair colour change. Lancet 1991;338:1520.

194. Daniel CR 3rd. Onycholysis: an overview. Semin Dermatol 1991;10:34-40.

195. Femiano F, Lanza A, Buonaiuto C, Gombos F, Rullo R, Festa V, et al. Oral manifestations of adverse drug reactions: guidelines. J Eur Acad Dermatol Venereol 2008;22:681-91.

196. Gómez-Moreno G, Guardia J, Aguilar-Salvaterra A, Cabrera-Ayala M, Maté-Sánchez de-Val JE, Calvo-Guirado JL. Effectiveness of malic acid 1% in patients with xerostomia induced by antihypertensive drugs. Med Oral Patol Oral Cir Bucal 2013;18:e49-55.

197. Madinier I, Berry N, Chichmanian RM. Drug-induced oral ulcerations. Ann Med Interne (Paris) 2000;151:248-54.

198. Aksdal E, Stokke T, Løkken P. Methylidopa – Mouth mucosa ulcerations. Nor Tannlaegeforen Tid 1979;89:504-5.

199. Mikeljevic J, Highet AS. Nicorandil-induced leg ulceration without mucosal involvement. Clin Exp Dermatol 2011;36:372-3.

200. Samarasinghe YP, Cox A, Feher MD. Calcium channel blocker induced gum hypertrophy: no class distinction. Heart 2004;90:16.

201. Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 2008;31:21-37.

202. Lamminantausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol 2005;152:968-74.

203. Goldberg I, Gilburd B, Kravitz MS, Kivity S, Chaim BB, Klein T, et al. A novel system to diagnose cutaneous adverse drug reactions employing the celsscan – Comparison with histamine releasing test and Inf-gamma Releasing Test. Clin Dev Immunol 2005;12:85-90.